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 Human thymidine phosphorylase (dThdPase) catalyses 
reversible phosphorylation of thymidine to deoxyribose-1-
phosphate and thymine, and is identical to Platelet-derived 
endothelial cell growth factor (PD-ECGF), which is an 
angiogenic factor purified from human platelet. In this 
study, we determined dThdPase expression levels in urinary 
tract cancer by enzyme-linked immunosorbent assay and 
determined whether they correlated with tumor stage and 
grade in bladder cancer. The mean level of dThdPase expres-
sion in cancer tissue was higher than in normal tissue in 
bladder cancer (41.1±50.7 unit/mg protein vs 17.6±17.8 unit/ 
mg protein) and in upper urinary tract cancer (52.4 ± 53.1 
unit/mg protein vs 17.6 ± 17.8 unit/mg protein). dThdPase 
expression level was correlated with tumor grade and stage 
in bladder cancer. These data suggest that dThdPase/PD-
ECGF is an important angiogenic factor for growth and 
extension of urinary tract cancer.
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Introduction 
 Tumor angiogenesis is the formation of new vessels 
toward and within a tumor, resulting in tumor growth and 
metastasis. Recently, there have appeared several reports 
concerning angiogenesis in bladder cancer. Tumor 
angiogenesis was reported as an independent prognostic 
indicator for patients with invasive transitional cell 
carcinoma of the bladder in a microvessel density study"). 
Increased expression of basic fibroblast growth factor and 
vascular endothelial cell growth factor, which are well-
known angiogenic growth factors have been recognized in 
bladder cancer,"). 
 Human thymidine phosphorylase (dThdPase), an en-
zyme involved in pyrymidine nucleotide metabolism, is 
known to be identical with Platelet-derived endothelial cell
growth factor (PD-ECGF), an angiogenic factors). PD-
ECGF is expressed in macrophages, stromal cells, and glial 
cells of normal tissue and is not expressed in normal 
gastrointestinal epithelium, bladder epithelium, or 
smooth muscle by the immunohistochemical methods'. The 
PD-ECGF/dThdPase expression levels in several kinds of 
cancer (colon, breast, and gastric) were higher than those 
in the surrounding normal tissues','). In this study, we 
investigated PD-ECGF/dThdPase expression levels and 
sites of dThdPase/PD-ECGF in urinary tract cancer and 
surrounding normal tissues using enzyme-linked immu-
nosorbent assay (ELISA) and immunohistochemical 
methods.
Address Correspondence : 
Dr. Kenji Sawase, Department of Urology, 
Nagasaki University School of Medicine, 1-7-1 Sakamoto, 
Nagasaki 852-8501, Japan
Patients and methods 
Patients 
 Specimens were obtained from 13 patients (11 men, 2 
women) with upper urinary tract transitional cell carci-
noma (TCC) and 35 patients (27 men, 8 women) with 
bladder TCC. The pathological stage and grade of the 
tumor were diagnosed by special pathologists according to 
TNM criteria. 
Reagent 
 Mouse monoclonal antibody MoAb 104B, MoAb 232-2 
and MoAb 654-1, which recognizes human dThdPase, was 
kindly provided by Nippon Roche Co. Ltd., Tokyo, Japan. 
These monoclonal antibodies were prepared using 
dThdPase purified from human colon cancer xenograft 
HCT 116 in mice'). 
ELISA 
 Tumor and normal epithelial tissues were obtained from 
each patient and were packed in ice, and stored at -801C 
until use for ELISA. Each tissue was homogenized in 10 
mM Tris-HCl buffer (pH 7.4) containing 15 mM NaCl, 1.5 
MM MgCl2 and 50 mM potassium phosphate, and then
centrifuged at 105000 xg for 90 min. The supernatant was 
dialyzed overnight against 20 mM potassium phosphate 
buffer (pH 7.4) and 1 mM 2-mercaptethanol, and was then 
used as a souse of crude dThdPase9. The protein concentra-
tion was determined by the method descrived by Lowry et 
al'. The amount of dThdPase was calibrated with that 
measured for standard solutions, and was evaluated as 
unit/tissue protein volume (mg)". 
 A 96-well microtiter plate (Nunc-immuno-plate Maxi-
sorp, Nunc, Roskilde, Denmark) was incubated at 4 C 
overnight with 10,a g/ml of the dThdPase MoAb 104B in 10 
mM phosphate buffered saline solution (PBS, pH 7.6). The 
plate was coated with 3% (w/v) skim milk in PBS (block-
ing buffer) for 1 hour at room temperature. The plate was 
washed with PBS containing 0.05% Tween 20 and 0.05% 
sodium azide and kept at 4 C until use. Test samples and 
standard solutions of dThdPase, which are HCT 116 tumor 
homogenates serially diluted with a blocking buffer, were 
dispensed onto the plate coated with antibody. The plate 
was incubated [1] at 37°C for 1 hour and then washed with 
0.05% Tween 20 in PBS ; [21 incubated with MoAb 232-2 at 
1p g/ml in blocking buffer for 1 hour at 37t and washed ; 
[3] incubated with 2000-fold diluted anti-mouse IgG 
conjugated with horseradish peroxidase (Bio-Rad, 
Hercules, CA) for 30 min at 37t and washed ; [4] incu-
bated with a substrate solution containing 3,3',5,5'-
tetramethylbenzidine (TMB) and H202 (TMB microwell 
peroxidase substrate system, KPL, Goithersgurs, MD) for 
10 to 20 min at room temperature. The peroxidase reaction 
was stopped by the addition of 1 M phosphate solution, 
and the amount of dThdPase sandwiched with the two 
anti-dThdPase MoAb was estimated by measuring its 
absorbency at 450 nm with a plate reader (Bio-Rad, model 
3550).
PD-ECGF/dThdPase Immunohistochemistory 
 Formalin-fixed paraffin-embedded sections were placed 
on silan coated glass slides (MASTUNAMI, Japan). The 
deparaffinized sections were placed in 0.1 M citrate buffer 
(pH 6.0) and heated twice in a microwave oven for 5 min. 
The primary antibody MoAb 654-1 was applied at a 
dilution of 1: 1000 and visualized by the alkaline 
phosphotase anti-alkaline phosphotase method. The slides 
were counterstained with 2% methylgreen and mounted. 
Statistics 
 The relationships between dThdPase expression levels 
and categorical variables were evaluated using the Mann-
Whitney U test and t test. A P value of less than 0.05 was 
considered statistically significant.
Results
PD-ECGF/dThdPase expression in transitional cell carci-
noma and surrounding normal tissue 
 PD-ECGF/dThdPase expression of bladder cancer tissue 
was higher than that of the normal tissue (41.1:-± 50.7 
unit/mg protein vs 17.6 ± 17.8 unit/mg protein). The 
expression level in upper urinary tract cancer tissue was 
also higher than that of the normal tissue (52.4 ± 53.1 
unit/mg protein vs 17.6 ± 17.8 unit/mg protein) (Fig. 1). 
There was a significant difference between cancer and 
normal tissue.
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Fig. 1 dThdPase expression level in normal epithelial tissue 
and cancer tissue.
Relationship between dThdPase expression level and 
pathological stage and grade in bladder cancer 
 The mean expression levels were 94.8 ± 80.5 unit/mg 
protein in invasive tumor, 30.5 ± 22.6 unit/mg protein in 
T1 tumor, and 9.9±7.7 unit/mg protein in Ta tumor (Fig. 
2). Thus, the level of dThdPase expression was increased in 
progressing stages of bladder cancer. There was a signifi-
cant difference in dThdPase expression level between Ta 
and T1 (p=0.04), as well as between Ta and invasive 
tumor (p=0.02). The level of dThdPase expression in G3 
bladder cancer (61.9±64.9 unit/mg protein) was-3 times as 
high as in G1 (20.4 ± 12.9 unit/mg protein) and twice as 
high as in G2 (34.7 ± 47.0 unit/mg protein). There was a 
significant difference in dThdPase expression between G1 
and G2 or G3. Elevation of dThdPase expression was found 
to parallel increases in histologic grade and progression of 
bladder cancer (Fig. 3).
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 Fig. 2 dThdPase expression level in superficial (stage Ta 
 and T1) and invasive (stage T2-T4) bladder cancer. 
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Fig. 4-a Section from the bladder cancer specimen, showing 
both nucleus and cytoplasm expressing for PD-ECGF/ 
dThdPase (x200).
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Fig. 3 dThdPase expression level in bladder cancer of 
different grades.
Fig. 4-b Interstitial cells in a superficial bladder cancer 
specimen were positively stained for PD-ECGF/dThdPase, 
and cancer cells were not stained (x100).
Immunohistochemistory 
 The usual pattern of PD-ECGF/dThdPase expression 
was primarily seen in cytoplasm and sometimes in both 
the nucleus and cytoplasm in cancer cells (Fig. 4-a). 
Normal epithelial cells were not stained for PD-ECGF/ 
dThdPase. The interstitial cells and the endothelial cells in 
tumor vessels were positively stained for PD-ECGF/ 
dThdPase in several patients (Fig. 4-b). Furthermore, 
dThdPase immunoreactivity in interstitial cells was 
observed in patients with highly dThdPase expression.
Discussion 
 There are 2 previous studies about the relationship 
between PD-ECGF/dTdRPase expression and tumor grade 
and stage in bladder cancer. Kubota et al. examined
dThdPase activity by enzyme assay, and Mizutani et al. 
examined levels of PD-ECGF expression by high perform-
ance liquid chromatography and enzyme-linked immu-
nosorbent assay","). As in our study, their findings 
suggested a correlation between PD-ECGF/dTdRPase 
expression and tumor stage and grade. In the present 
study, the author demonstrated that the expression of 
dThdPase was increased in urinary tract cancer compared 
with surrounding normal tissue. In bladder cancer, stage 
progression and increased pathological grade correlated 
with dThdPase expression. Furthermore, the expression of 
dThdPase in T1 bladder cancer was significantly higher 
than that in Ta bladder cancer, and there were no signifi-
cant differences between Ta cancer tissue and normal 
epithelium. These results suggested that submucosal 
infiltration of cancer cells may be the first step in inducing 
the expression of dThdPase. However, further studies are 
needed to clarify the relatoinship between dThdPase 
expression and tumor extension. 
 Angiogenesis is induced by various angiogenic factors 
produced by cancer cells or non-malignant cells that 
infiltrate the cancer. In this study, dThdPase immu-
noreactivity was observed not only in cancer cells but also 
in interstitial cells in patients with highly dThdPase 
expressing. These results suggest that dThdPase/PD-ECGF 
may be produced by cancer cells and interstitial cells in 
urinary tract cancer. 
 5'-Deoxy-5-fuluorouridine (5'-dFUrd : Furtulon®) ex-
hibits antitumor activity through its conversion to 5-
fluorouracil by dThdPase9. Clinically, high stages and 
grades of urinary tract cancer have more malignant 
potential, and a high incidence of recurrence and progres-
sion is a serious problem. In this study, a high-stage and 
high-grade tumor expressed a high level of dThdPase. 
Therefore, treatment with 5'-dFUrd may be effective in 
these tumors. 
 In conclusion, the current study demonstrated that the 
expression of dThdPase/PD-ECGF was increased in uri-
nary tract cancer compared with normal tissue, and 
elevation of dThdPase/PD-ECGF expression correlated 
with progression stage and grade increase in bladder 
cancer.
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